Last updated: July 13, 2026
Litigation summary and analysis: Sun Pharmaceutical Industries, Ltd. v. Solaris Pharma Corporation (2:26-cv-04286)
Executive summary: The docket entry provided identifies the case caption and filing number (2:26-cv-04286) but contains no substantive litigation information: no asserted patents, no Orange Book/NDA/BLA reference, no causes of action (e.g., Paragraph IV under 35 U.S.C. § 271(e)(2)), no claims/construction, no motion practice, no schedule, no settlement, and no court orders. No litigation summary or analysis can be produced from the available data.
What case is Sun Pharmaceutical Industries, Ltd. v. Solaris Pharma Corporation (2:26-cv-04286)?
There is no docket content in the input beyond the case identifier, so there is no verifiable information on:
- Which court and division are involved beyond the filing number format
- Whether the action is a Hatch-Waxman patent infringement case or another IP theory
- Whether the suit targets a specific ANDA, NDA, or biologics license application (BLA)
What patents are asserted in Sun v. Solaris Pharma (2:26-cv-04286)?
No asserted patent numbers, listed patents, expiration dates, or claims-in-suit are provided, so the asserted estate cannot be summarized.
Are asserted patents Orange Book-listed patents for a specific drug?
No NDA/BLA or Orange Book listing is provided, so there is no basis to map patents to:
- Listed NDA/BLA drug products
- Patent categories (drug substance, drug product, method of use)
- Listed expiration and regulatory exclusivity drivers
What drug does the litigation involve in 2:26-cv-04286?
The input provides no drug name, active ingredient, strength, dosage form, or application number. A drug-level litigation analysis cannot be generated.
What is the procedural posture of 2:26-cv-04286 (complaint, TRO, preliminary injunction, motions)?
No complaint, no scheduling order, and no order text is provided, so the procedural posture is unknown:
- Whether a preliminary injunction or TRO was sought or granted
- Whether motions to dismiss, transfer, stay, or claim construction are pending
- Whether the parties proceeded under standard Hatch-Waxman timelines
Has Solaris Pharma filed an ANDA Paragraph IV notice, and what certifications are at issue?
No ANDA number, no Paragraph IV notice date, and no certification details are included. Without those, there is no basis to analyze:
- The “A” through “N” certification type (e.g., “IV”)
- The listed patents targeted by the notice
- NDA labeling carve-outs or carve-out litigation theories
What settlement terms exist (if any) for Sun v. Solaris (2:26-cv-04286)?
No settlement agreement, consent judgment, licensing terms, or payment details are provided. A settlement analysis cannot be produced.
How strong is Sun’s patent estate versus Solaris’s generic entry risk?
No patents, no remaining life, and no infringement/validity positions are provided. Strength cannot be assessed using:
- Remaining patent term at filing
- Independent claim counts and breadth
- Prior art landscape
- Known district-court or Federal Circuit outcomes
- Claim construction risk
What generic entry risks exist for Solaris Pharma based on 2:26-cv-04286?
No ANDA status, no tentative approval date, no FDA bottlenecks, and no injunction status is provided. The risk cannot be mapped to:
- 180-day exclusivity
- Patent-by-patent injunction landscape
- Label design changes to avoid infringement
What Orange Book status is relevant to 2:26-cv-04286?
No Orange Book entries or listed patents are included in the input, so there is no basis to state:
- Listed patents by number and expiration
- Exclusivity periods
- Regulatory exclusivity layering (market exclusivity, pediatric exclusivity)
Which companies are involved and what roles do they play?
The input only provides the plaintiff and defendant names. It does not include:
- Additional defendants (e.g., subsidiaries, distributors)
- Counterclaimants
- Contract research/manufacturing entities implicated in infringement
Key Takeaways
- The provided information identifies the litigation by case caption and docket number only.
- There is no asserted-patent, procedural, or regulatory detail to support a litigation summary or business-grade analysis.
- A factual patent and exclusivity analysis for this case cannot be constructed from the available input.
FAQs
1) What court is handling case 2:26-cv-04286?
No court location, division, or judge is provided in the input.
2) Which patents are listed in the complaint for Sun v. Solaris?
No patent numbers are provided.
3) Is this case a Paragraph IV Hatch-Waxman action under 35 U.S.C. § 271(e)(2)?
No cause of action or ANDA/NDA framework is provided.
4) Are there any published orders in 2:26-cv-04286?
No orders or docket events are provided.
5) Does the case include any settlement or consent judgment?
No settlement terms or final disposition are provided.
References
(No sources were cited because the input contains no docket text, complaint allegations, orders, or patent identifiers to support citations.)
